Nucleic Acid Testing
This article was originally published in The Gray Sheet
Executive SummaryFDA will accept comments on its draft guidance entitled "Application of Current Statutory Authority to Nucleic Acid Testing of Pooled Plasma" until Jan. 25, 2000 according to a Nov. 26 notice in the Federal Register. The guidance seeks public comment on the development and implementation of nucleic acid testing for infectious agents "when such testing is intended for use in blood donor screening and/or manufacturing of blood products"
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.